REPLIGEN CORP Net Cash Provided by (Used in) Investing Activities, Continuing Operations
REPLIGEN CORP (RGEN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.56 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$1.56M, a 125.74% decline year-over-year.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$1.17M.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$111.21M.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $8.05M.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$98.25M.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$49.19M, a 1126.80% decline from fiscal 2015.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $4.79M.
- REPLIGEN CORP net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$19.79M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$1.56M 10-Q · filed 2018-05-08 | -$2.73M derived: sum of 2 quarters · filed 2018-05-08 | -$113.94M derived: sum of 3 quarters · filed 2018-05-08 | -$105.89M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$112.38M derived: sum of 2 quarters · filed 2018-02-22 | -$104.32M derived: sum of 3 quarters · filed 2018-02-22 | -$98.25M 10-K · filed 2018-02-22 | ||||
| 2017-09-30 | -$111.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$103.15M derived: sum of 2 quarters · filed 2017-11-09 | -$97.08M 10-Q · filed 2017-11-09 | -$132.39M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-06-30 | $8.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $14.13M 10-Q · filed 2017-08-03 | -$21.18M derived: sum of 3 quarters · filed 2018-05-08 | -$35.08M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-03-31 | $6.08M 10-Q · filed 2018-05-08 | -$29.24M derived: sum of 2 quarters · filed 2018-05-08 | -$43.14M derived: sum of 3 quarters · filed 2018-05-08 | -$44.32M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | -$35.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$49.21M derived: sum of 2 quarters · filed 2018-02-22 | -$50.39M derived: sum of 3 quarters · filed 2018-02-22 | -$49.19M 10-K · filed 2018-02-22 | ||||
| 2016-09-30 | -$13.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$15.08M derived: sum of 2 quarters · filed 2017-11-09 | -$13.88M 10-Q · filed 2017-11-09 | -$11.21M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $20.00K 10-Q · filed 2017-08-03 | $2.69M derived: sum of 3 quarters · filed 2018-02-22 | $4.31M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | $1.20M 10-Q · filed 2017-05-04 | $3.87M derived: sum of 2 quarters · filed 2018-02-22 | $5.49M derived: sum of 3 quarters · filed 2018-02-22 | $5.71M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $4.29M derived: sum of 2 quarters · filed 2018-02-22 | $4.51M derived: sum of 3 quarters · filed 2018-02-22 | $4.79M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.84M derived: sum of 2 quarters · filed 2016-11-03 | $2.12M 10-Q · filed 2016-11-03 | $896.00K derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $503.00K 10-Q · filed 2016-08-04 | $503.10K 10-Q · filed 2015-08-06 | -$720.00K derived: sum of 3 quarters · filed 2017-02-23 | -$2.44M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | $279.00K 10-Q · filed 2016-05-05 | $279.16K 10-Q · filed 2015-05-08 | -$944.00K derived: sum of 2 quarters · filed 2017-02-23 | -$2.66M derived: sum of 3 quarters · filed 2017-02-23 | -$20.47M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$2.94M derived: sum of 2 quarters · filed 2017-02-23 | -$20.75M derived: sum of 3 quarters · filed 2017-02-23 | -$19.79M 10-K · filed 2017-02-23 | -$19.79M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$19.53M derived: sum of 2 quarters · filed 2015-11-05 | -$18.57M 10-Q · filed 2015-11-05 | -$18.57M 10-Q · filed 2014-11-07 | -$28.59M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | -$17.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$16.85M 10-Q · filed 2015-08-06 | -$26.88M derived: sum of 3 quarters · filed 2016-02-25 | -$28.95M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $961.63K 10-Q · filed 2015-05-08 | -$9.06M derived: sum of 2 quarters · filed 2016-02-25 | -$11.13M derived: sum of 3 quarters · filed 2016-02-25 | -$11.90M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | -$10.03M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$12.10M derived: sum of 2 quarters · filed 2016-02-25 | -$12.86M derived: sum of 3 quarters · filed 2016-02-25 | -$17.91M 10-K · filed 2016-02-25 | -$17.91M 10-K · filed 2015-03-17 | |||
| 2013-09-30 | -$2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$2.83M derived: sum of 2 quarters · filed 2014-11-07 | -$7.88M 10-Q · filed 2014-11-07 | |||||
| 2013-06-30 | -$761.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$5.81M 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | -$5.05M 10-Q · filed 2014-05-09 | |||||||
| 2012-12-31 | $2.84M 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |